Please use this identifier to cite or link to this item:
Title: Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimer's disease
Austin Authors: Sabbagh, Marwan N;Schäuble, Barbara;Anand, Keshav;Richards, Danielle;Murayama, Shigeo;Akatsu, Hiroyasu;Takao, Masaki;Rowe, Christopher C ;Masters, Colin L ;Barthel, Henryk;Gertz, Hermann-Josef;Peters, Oliver;Rasgon, Natalie;Jovalekic, Aleksandar;Sabri, Osama;Schulz-Schaeffer, Walter;Seibyl, John
Affiliation: Alzheimer’s and Memory Disorders Division, Barrow Neurological Institute, Phoenix, AZ, USA
Formerly Piramal Imaging GmbH, Berlin, Germany
Banner Sun Health Research Institute, Sun City, AZ, USA
Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
Fukushimura Hospital, Toyohashi, Japan
Departments of Community-based Medicine and Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Aichi, Japan
Mihara Memorial Hospital, Isesaki, Japan
Austin Health, University of Melbourne, Heidelberg, Victoria, Australia
The Florey Institute, The University of Melbourne, Australia
Department of Nuclear Medicine, Leipzig University, Leipzig, Germany
Department of Psychiatry, Leipzig University, Leipzig, Germany
Department of Psychiatry and Psychotherapy, Charité Berlin, Berlin, Germany
Department of Psychiatry, Stanford School of Medicine, Stanford, USA
Piramal Imaging GmbH, Berlin, Germany
Georg-August University Göttingen, Göttingen, Germany
Molecular Neuroimaging, New Haven, CT, USA
Issue Date: 24-Jan-2017
Publication information: Journal of Alzheimer's Disease 2017; 56(2): 441-446
Abstract: Of 57 individuals diagnosed with Alzheimer’s disease (AD) in a phase III study, 13 (23%) had amyloid-β (Aβ) levels on postmortem histopathology that did not explain the dementia. Based on postmortem histopathology, a wide range of different non-AD conditions was identified, including frontotemporal dementia, hippocampal sclerosis, and dementia with Lewy bodies. Of the histopathologically Aβ negative scored cases ante-mortem Florbetaben PET scans were classified as negative for Aβ in 11 patients based on visual analysis and in all 12 quantifiable cases based on composite standardized uptake value ratios. Thus, florbetaben PET can assist physicians in the differential diagnosis of neurodegenerative disorders by reliably excluding Aβ pathology.
DOI: 10.3233/JAD-160821
ORCID: 0000-0003-3910-2453
PubMed URL:
Type: Journal Article
Subjects: Alzheimer’s disease
Florbetaben PET
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 6, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.